West Coast Sarcoma Conference 2024: Session 2 – Retroperitoneal Liposarcoma: What’s the Difference?

West Coast Sarcoma Conference 2024: Session 2 – Retroperitoneal Liposarcoma: What’s the Difference?

West Coast Sarcoma Conference

Access chapters by clicking on the chapter button in the video player above icon-vimeo-chapters

Icon Chair Speaker

Chair

Dr. Caroline Holloway

Icon Chair Speaker

Speakers

Dr. Rebecca Gladdy
Dr. Cheng-Han Lee
Dr. Manish Dhyani
Dr. Saranya Kakumanu
Dr. Harveshp Mogal
Dr. Albiruni Razak

Studies/trials discussed:

  • Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group
  • Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial
  • Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years
  • A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)
  • Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database
  • Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma
  • A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
  • A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
  • Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
  • A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.
  • A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
  • Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Tagged